DBV Technologies (DBVT) Research & Development (2014 - 2026)
DBV Technologies (DBVT) reported Research & Development of $33.4 million for Q1 2026, up 55.35% year-over-year from $21.5 million in Q1 2025, and up 1.54% on a QoQ basis from $32.9 million in Q4 2025.
DBV Technologies (DBVT) has 12 years of Research & Development data on file, last reported at $33.4 million in Q1 2026.
- Quarterly Research & Development rose 55.35% year-over-year to $33.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.6 million (up 43.78% YoY) and the FY2025 annual result came in at $116.7 million, up 30.6% from the prior year.
- Research & Development grew to $33.4 million in Q1 2026 per DBVT's latest filing, from $32.9 million in the prior quarter.
- Across five years, Research & Development topped out at $33.7 million in Q2 2025 and bottomed at $12.2 million in Q1 2022.
- The 5-year median for Research & Development is $21.4 million (2024), against an average of $22.1 million.
- The widest annual swing landed in 2022, when Research & Development jumped 153.69%; it then tumbled 56.86% in 2023.
- Tracing DBVT's Research & Development over 5 years: stood at $29.6 million in 2022, then plunged by 56.86% to $12.8 million in 2023, then soared by 47.98% to $18.9 million in 2024, then soared by 73.99% to $32.9 million in 2025, then climbed by 1.54% to $33.4 million in 2026.
- Per Business Quant, the three latest DBVT Research & Development figures stand at $33.4 million (Q1 2026), $32.9 million (Q4 2025), and $28.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 33.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.40 Mn |
| Dec 31, 2025 | 32.89 Mn |
| Sep 30, 2025 | 28.62 Mn |
| Jun 30, 2025 | 33.69 Mn |
| Mar 31, 2025 | 21.50 Mn |
| Dec 31, 2024 | 18.90 Mn |
| Sep 30, 2024 | 23.66 Mn |
| Jun 30, 2024 | 25.37 Mn |
| Mar 31, 2024 | 21.40 Mn |
| Dec 31, 2023 | 12.78 Mn |
| Sep 30, 2023 | 13.80 Mn |
| Jun 30, 2023 | 17.62 Mn |
| Mar 31, 2023 | 16.04 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 15.10 Mn |
| Jun 30, 2022 | 18.61 Mn |
| Mar 31, 2022 | 12.22 Mn |
| Dec 31, 2021 | 11.67 Mn |
| Sep 30, 2021 | 16.32 Mn |
| Jun 30, 2021 | 20.18 Mn |
| Mar 31, 2021 | 22.16 Mn |
| Dec 31, 2020 | 26.39 Mn |
| Sep 30, 2020 | 25.75 Mn |
| Jun 30, 2020 | 21.93 Mn |
| Mar 31, 2020 | 27.53 Mn |
| Sep 30, 2019 | -23.85 Mn |
| Dec 31, 2018 | -34.58 Mn |
| Sep 30, 2018 | -31.32 Mn |
| Jun 30, 2016 | -37.16 Mn |
| Jun 30, 2015 | -13.81 Mn |
| Jun 30, 2014 | -14.32 Mn |